Jan 13 (Reuters) - The U.S. Food and Drug Administration on Tuesday requested companies to remove warnings related to the potential risk of suicidal ideation and behavior from the labeling of popular weight-loss drugs of the GLP-1 class.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.